EGAS00001001778-sc-20160427 - samples

ABSTRACT: KRAS mutant CRC is currently in clinical trial with a combination of a MEK and Akt inhibitor. These patients will likely develop resistance to this combination. We aim to identify the mechanisms of resistance via ENU mutagenesis, with a view to identifying additional therapeutics which have the ability to overcome this resistance.

PROVIDER: EGAD00001002066 | EGA |

REPOSITORIES: EGA